MAPT and Alzheimer disease: Presently, most studies have shown that SCFA mainly antagonizes AD in three ways: through the anti-inflammatory reaction, reducing Tau protein phosphorylation caused by Aβ plaque, and increasing neuroactive substances to improve memory and cognition [79,93].